Related Experiment Video
Updated: Jun 9, 2026

Probiotic Studies in Neonatal Mice Using Gavage
Published on: January 27, 2019
Meta-analysis and systematic review: efficacy of probiotics in combination with standard therapies for rotavirus
Xiang Gao1, Hui Zhang1, Yangyang Yu1
1Clinical College of Traditional Chinese Medicine, Inner Mongolia Medical University, Hohhot, China.
Background:
Rotavirus enteritis is the main cause of hospitalization and death in patients with diarrhea. There is no specific drug. Vaccine prevention is effective, but the oral route has safety concerns in developing countries. A safe and effective treatment is urgently needed.
Objective:
To systematically evaluate the clinical analysis of conventional therapy combined with probiotics in patients with rotavirus enteritis.
Materials And Methods:
We retrieved a total of 14 randomized controlled trials (RCTs) involving 1709 patients from multiple databases.
Results:
Results showed that probiotics significantly shortened recovery times for defecation frequency [mean difference (MD) = 1.18, 95% confidence interval (CI): 0.76-1.60, P < 0.00001], antidiarrheal time (MD = 1.17, 95% CI: 1.02-1.32, P < 0.00001), body temperature recovery (MD = 0.83, 95% CI: 0.58-1.08, P < 0.00001), and vomiting cessation (MD = 1.00, 95% CI: 0.61-1.39, P < 0.00001). Immunoglobulin levels (IgA and IgG) also improved significantly. The experimental group demonstrated a higher total effective rate [relative risk (RR) = 0.85, 95% CI: 0.82-0.88, P < 0.00001] and comparable safety (RR = 1.38, 95% CI: 0.74-2.56, P > 0.05).
Conclusion:
Probiotics, by regulating gut microbiota and enhancing mucosal immunity, offer a safe and effective adjunct to conventional therapy for rotavirus enteritis.
Related Concept Videos
Probiotics
Microbiota Modulation by Antibiotics
Bacterial Gastroenteritis
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Microorganisms in Medicine and Therapeutics
